TELA Bio Announces US Commercial Launch of OviTex PRS Long-Term Resorbable for Plastic and Reconstructive Surgery
Portfolio Pulse from Benzinga Newsdesk
TELA Bio, Inc. (NASDAQ:TELA) has announced the US commercial launch of their product, OviTex PRS Long-Term Resorbable. The product is intended for implantation to reinforce soft tissue in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.
August 16, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TELA Bio's launch of OviTex PRS Long-Term Resorbable could potentially increase the company's market share in the medical technology sector.
The launch of a new product typically indicates a company's growth and expansion. This could potentially attract more investors, leading to an increase in the company's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100